



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 November 2017  
EMA/HMPC/325716/2017  
Committee on Herbal Medicinal Products (HMPC)

## European Union herbal monograph on *Hedera helix* L., folium

Final

<b>Initial assessment</b>	
Discussion in Working Party on European Union monographs and list (MLWP)	May 2009 November 2009 January 2010
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	14 January 2010
End of consultation (deadline for comments)	15 June 2010
Re-discussion in MLWP	September 2010 November 2010 January 2011 March 2011
Adoption by HMPC Monograph (EMA/HMPC/289430/2009) Assessment Report (EMA/HMPC/289432/2009) List of references (EMA/HMPC/289429/2009) Overview of comments (EMA/HMPC/570419/2010)	31 March 2011
<b>First revision</b>	
Discussion in MLWP	September 2014 November 2014
Adoption by HMPC for release for consultation	28 January 2015
End of consultation (deadline for comments)	15 May 2015
Re-discussion in MLWP	September 2015
Adoption by HMPC	24 November 2015
<b>Second revision</b>	
Discussion in MLWP	May 2017
Adoption by HMPC	21 November 2017



Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; well-established medicinal use; <i>Hedera helix</i> L., folium; Hederae helicis folium; Ivy leaf
----------	---

BG (bulgarski): Бръшлян, лист	LT (lietuvių kalba): Gebenių lapai
CS (čeština): břečťanový list	LV (latviešu valoda): Vijīgās efejas lapas
DA (dansk): Vedbendblad	MT (Malti): werqa tal-Liedna
DE (Deutsch): Efeublätter	NL (Nederlands): Klimop
EL (elliniká): Φύλλο κισσού	PL (polski): Liść bluszczu
EN (English): ivy leaf	PT (português): hera, folha
ES (español): hiedra, hoja de	RO (română): frunză de iederă
ET (eesti keel): luuderohuleht	SK (slovenčina): list brečtana
FI (suomi): muratti, lehti	SL (slovenščina): list navadnega bršljana
FR (français):	SV (svenska): murgröna, blad
HR (hrvatski): bršljanov list	IS (íslenska):
HU (magyar): borostyánlevél	NO (norsk): eføyblad
IT (italiano): Edera foglia	

# European Union herbal monograph on *Hedera helix* L., folium

## 1. Name of the medicinal product

To be specified for the individual finished product.

## 2. Qualitative and quantitative composition<sup>1,2</sup>

Well-established use	Traditional use
<p>With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC</p> <p><i>Hedera helix</i> L., folium (ivy leaf)</p> <p>i) Herbal substance</p> <p>Not applicable</p> <p>ii) Herbal preparations</p> <p>a) Dry extract (DER 4-8:1), extraction solvent ethanol 24-30% m/m</p> <p>b) Dry extract (DER 6-7:1), extraction solvent ethanol 40% m/m</p> <p>c) Dry extract (DER 3-6:1), extraction solvent ethanol 60% m/m</p> <p>d) Liquid extract (DER 1:1), extraction solvent ethanol 70% V/V</p> <p>e) Soft extract (DER 2.2-2.9:1), extraction solvent ethanol 50% V/V: propylene glycol (98:2)</p>	

## 3. Pharmaceutical form

Well-established use	Traditional use
<p>Herbal preparations in liquid or solid dosage forms for oral use.</p> <p>The pharmaceutical form should be described by the European Pharmacopoeia full standard term.</p>	

<sup>1</sup> The material complies with the Ph. Eur. monograph (ref.: 2148).

<sup>2</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

## 4. Clinical particulars

### 4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product used as an expectorant in case of productive cough.	

### 4.2. Posology and method of administration

Well-established use	Traditional use
<p><b>Posology</b></p> <p><i>Adolescents, adults and elderly</i></p> <p>a) Single dose: 15-65 mg, one to three times daily Daily dose: 45-105 mg (Note: maximum daily dose for ethanol-containing finished products : 67 mg; corresponding to 420 mg herbal substance)</p> <p>b) Single dose: 14-18 mg three times daily Daily dose: 42-54 mg</p> <p>c) Single dose: 33 mg two times daily Daily dose: 66 mg</p> <p>d) Single dose: 100 mg three times daily Daily dose: 300 mg</p> <p>e) Single dose: 40 mg three times daily Daily dose: 120 mg</p> <p><i>Children between 6-11 years of age</i></p> <p>a) Single dose: 11-35 mg, two to three times daily Daily dose: 33-70 mg. (Note: maximum daily dose for ethanol-containing finished products: 34 mg; corresponding to 210 mg herbal substance)</p> <p>b) Single dose: 9-18 mg, one to three times daily Daily dose: 15-40 mg</p> <p>c) Single dose: 25 mg, two times daily Daily dose: 50mg</p> <p>d) Single dose: 75 mg, three times daily Daily dose: 225 mg</p> <p>e) Single dose: 20-26 mg, three to four times Daily Daily dose: maximum of 80 mg</p>	

Well-established use	Traditional use
<p><i>Children between 2-5 years of age</i></p> <p>a) Single dose: 8-18 mg, two to three times daily Daily dose: 24-36 mg (Note: maximum daily dose for ethanol-containing finished products: 24 mg; corresponding to 150 mg herbal substance)</p> <p>b) Single dose: 7-9 mg, two to three times daily Daily dose: 14-27 mg</p> <p>c) Single dose: 17 mg, two times daily Daily dose 34 mg</p> <p>e) Single dose: 20 mg, three times daily Daily dose: 60 mg</p> <p>The use in children under 2 years of age is contraindicated (see section 4.3. 'Contraindications').</p> <p><b>Duration of use</b></p> <p>If the symptoms persist longer than one week during the use of the medicinal product, a doctor or a pharmacist should be consulted.</p> <p><b>Method of administration</b></p> <p>Oral use</p>	

### 4.3. Contraindications

Well-established use	Traditional use
<p>Hypersensitivity to the active substance or to plants of the Araliaceae family.</p> <p>Children under 2 years of age because of the general risk of aggravation of respiratory symptoms through secretolytic drugs.</p>	

### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
<p>Persistent or recurrent cough in children between 2-4 years of age requires medical diagnosis before treatment.</p> <p>When dyspnoea, fever or purulent sputum occurs, a doctor or a pharmacist should be consulted.</p> <p>Caution is recommended in patients with gastritis</p>	

Well-established use	Traditional use
<p>or gastric ulcer.</p> <p>For extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.</p> <p>Preparation d) should not be administered to children under 6 years of age because of the alcohol content.</p>	

#### **4.5. Interactions with other medicinal products and other forms of interaction**

Well-established use	Traditional use
None reported	

#### **4.6. Fertility, pregnancy and lactation**

Well-established use	Traditional use
<p>Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.</p> <p>No fertility data are available.</p>	

#### **4.7. Effects on ability to drive and use machines**

Well-established use	Traditional use
No studies on the effect on the ability to drive and use machines have been performed.	

#### **4.8. Undesirable effects**

Well-established use	Traditional use
<p>Gastrointestinal reactions (nausea, vomiting, diarrhoea) have been reported. The frequency is not known.</p> <p>Allergic reactions (urticaria, skin rash, dyspnoea, anaphylactic reaction) have been reported. The frequency is not known.</p> <p>If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be</p>	

Well-established use	Traditional use
consulted.	

#### 4.9. Overdose

Well-established use	Traditional use
<p>Overdose can provoke nausea, vomiting, diarrhoea and agitation.</p> <p>One case of a 4 years old child who developed aggressivity and diarrhoea after accidental intake of an ivy extract corresponding to 1.8 g herbal substance has been reported.</p>	

## 5. Pharmacological properties

### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
<p>Pharmacotherapeutic group: respiratory system</p> <p>Proposed ATC code: R05 C</p> <p>The mechanism of action is not known.</p>	

### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
No data available.	

### 5.3. Preclinical safety data

Well-established use	Traditional use
Data on genotoxicity, carcinogenicity and reproductive toxicity testing for ivy leaf preparations are not available.	

## 6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable	

## 7. Date of compilation/last revision

21 November 2017